Modulation of TNF-α-induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide

YINGHUA JU1,4, JIAN HUA1, KOJI SAKAMOTO3, HIDEOKI OGAWA2 and ISAO NAGAOKA1

1Department of Host Defense and Biochemical Research, 2Atray (Allergy) Research Center, Juntendo University, School of Medicine, Hongo, Bunkyo-ku, Tokyo 113-8421; 3Koyo Chemical Co., Ltd., Iidabashi, Chiyoda-ku, Tokyo 102-0072, Japan; 4Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Medical University, Shenyang 110001, P.R. China

Received August 14, 2008; Accepted October 2, 2008

DOI: 10.3892/ijmm_00000089

Abstract. Atherosclerosis is now considered a chronic inflammatory disease, and glucosamine has the potential to exhibit an anti-inflammatory action. Thus, we investigated the effect of glucosamine on tumor necrosis factor α (TNF-α)-induced endothelial cell activation. Human umbilical vein endothelial cells (HUVECs) were stimulated by TNF-α in the presence or absence of glucosamine or its analogue, N-acetylglucosamine. mRNA expression of MCP-1 (a chemotactant protein) and ICAM-1 (an adhesion molecule) was evaluated by real-time RT-PCR, and their protein levels were analyzed by ELISA and Western blotting, respectively. Furthermore, the effects of glucosamine on the phosphorylation of p38MAPK and NF-κB, and O-N-acetylglucosamine (O-GlcNAc) modification were evaluated by Western blotting. The results demonstrated that glucosamine but not N-acetylglucosamine suppressed TNF-α-induced expression of MCP-1 and ICAM-1 at both the mRNA and protein levels. Furthermore, glucosamine abrogated the phosphorylation of p38MAPK and NF-κB. To note, glucosamine induced O-GlcNAc modification, which was negatively correlated with the expression of MCP-1 and ICAM-1, and phosphorylation of p38MAPK and NF-κB. Thus, glucosamine is likely to suppress endothelial cell activation (TNF-α-induced ICAM-1 and MCP-1 expression) possibly by affecting p38MAPK and NF-κB signaling via O-GlcNAc modification.

Introduction

In recent years, the findings of various clinical and pathological studies have altered the theories concerning the pathogenesis of atherosclerosis. Although large lipid deposits can be observed in atheromatous lesions and the role of different lipoproteins are thought to be involved in its pathogenesis, atherosclerosis is no longer considered to be a primary disorder of lipid accumulation (1). It is a state of disordered immunity in which there is dynamic interaction between endothelial dysfunction, inflammation and repeated cycles of ‘wound healing response’ (2). Expression of endothelial cell adhesion molecules such as intercellular adhesion molecule (ICAM-1), induces the binding of monocytes and lymphocytes, thus initiating an inflammatory process that ultimately leads to the formation of atherosclerotic plaque (3). The migration of inflammatory cells to the sub endothelial space is facilitated by chemotactants such as monocyte chemotactic protein-1 (MCP-1) and oxidized low-density lipoprotein (O,Lipo). Once migrated to the subendothelial space, monocytes mature into macrophages and express scavenger receptors to internalize modified lipoproteins, which give rise to lipid-laden macrophages or foam cells (6). Pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), are found in atherosclerotic lesions, and have been known to contribute to the inflammatory process (7). Previous studies have shown that these cytokines can induce the expression of cell adhesion molecules, chemokines and genes in endothelial cells involved in the regulation of vessel tonicity, thrombosis and recruitment of leukocytes (8).

Glucosamine, a naturally occurring amino monosaccharide, acts as a preferred substrate for the biosynthesis of glycosaminoglycan and has been used for the treatment of osteoarthritis more than two decades (9). Several short- and long-term clinical trials of osteoarthritis have shown the significant symptom-modifying effect of glucosamine with no side effects (10). Furthermore, glucosamine has been shown to inhibit the expression of inducible nitric oxide synthase in macrophages (11), and neutrophil functions such as superoxide generation, phagocytosis, granule enzyme release, chemotaxis and CD11b expression (12), thereby possibly exhibiting an anti-inflammatory action. More recently, glucosamine has been shown to inhibit ICAM-1 expression in human retinal pigment epithelial cells, which suggests a potential of glucosamine to attenuate inflammation in eyes (13). Based on these

Correspondence to: Dr Isao Nagaoka, Department of Host Defense and Biochemical Research, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan E-mail: nagaokai@juntendo.ac.jp

Key words: glucosamine, O-N-acetylglucosamine modification, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, endothelial cell
findings, we hypothesized that glucosamine may affect the endothelial cell activation. In this study, we investigated the effect of glucosamine on the activation of endothelial cells (expression of a monocyte chemoattractant factor MCP-1 and an adhesion molecule ICAM-1) induced by TNF-α, a cytokine expressed in atherosclerotic lesions, as a sequel to our previous research (14).

Materials and methods

Reagents. D-Glucosamine hydrochloride was supplied from Koyo Chemical Co. (Tokyo, Japan). N-Acetyl-D-glucosamine was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan); alloxan monohydrate from Sigma Chemical Co. (St. Louis, MO); TNF-α from Pepro Tech. EC Ltd. (London, UK); SB203580, a p38MAPK inhibitor and BMS-345541, an IKK (IκB kinase) inhibitor, which down-regulates NF-κB activation, from Calbiochem (Darmstadt, Germany).

Endothelial cells. Human umbilical vein endothelial cells (HUVECs) and endothelial cell medium EGM-2 were purchased from Sanko Junyaku Co. (Tokyo, Japan). HUVECs were maintained in EGM-2 medium at 37˚C in a CO2 incubator. HUVECs were incubated in the presence or absence of 0.1-10 mM glucosamine, or 1 and 10 mM N-acetylglucosamine for 2 h, and then stimulated with 0.5 ng/ml TNF-α for 24 h at 37˚C, unless otherwise noted. In some experiments, HUVECs were preincubated with 0.5 mM alloxan for 2 h, and were further incubated with 0.1-10 mM glucosamine for 2 h before stimulation with 0.5 ng/ml TNF-α. Alternatively, HUVECs were preincubated with SB203580 (5-20 μM) and BMS-345541 (1-4 μM) for 2 h before TNF-α stimulation.

Analysis of MCP-1 and ICAM-1 mRNA expression by real-time RT-PCR. HUVECs were plated at 1.5x105/well in 6-well plates in EGM-2 medium for 24 h at 37˚C (50-60% confluent). HUVECs were preincubated in the presence or absence of glucosamine or N-acetylglucosamine, and then stimulated with TNF-α. Thereafter, the total RNA was purified using a RNeasy Mini Kit (Qiagen, Valencia, CA), and RT-PCR was performed using a ReverTra Dash RT-PCR Kit (Toyobo, Osaka, Japan). First-strand cDNA was synthesized with total RNA (1 μg), a random primer and ReverTra Ace reverse transcriptase (Toyobo), and the RT-PCR was performed using 7500 Real-Time PCR System (Applied Biosystems, Warrington, UK). Analysis of the phosphorylation of p38MAPK and NF-κB. HUVECs (50-60% confluent in 6-well plates) were incubated in the presence or absence of 0.1-10 mM glucosamine or 1 mM N-acetylglucosamine for 2 h, and then stimulated with 0.5 ng/ml TNF-α for 10 min at 37˚C. After washing with PBS, the cells were harvested in 250 μl of lysis buffer (1% Triton X-100, 0.5% Nonidet P-40, 1 mg/ml Tris-HCl, 1 mM EDTA, 1 mM EGTA and 1 mM diisopropyl fluorophosphate) containing 1/25 v/v Complete™ (Roche Molecular Biochemicals, Mannheim, Germany). Lysates were placed on ice for 30 min and centrifuged at 14,000 x g for 10 min. The supernatants were recovered and mixed with sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample buffer and denatured at 100˚C for 3 min. Samples (10 μg protein/lane) were subjected to 10% SDS-PAGE, and separated proteins were transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA). The membranes were blocked in 5% skim milk and probed with rabbit anti-human ICAM-1 polyclonal antibody (H-108; Santa Cruz Biotechnology, Santa Cruz, CA). After washing with PBS-0.05% Tween, membranes were further probed with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Chemicon Int., Temecula, CA), and the proteins were finally detected with SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL). The detected bands were quantified using LAS-3000 image analyzer and MultiGauge software (Fujifilm Corp., Tokyo, Japan).

Thereafter, the antibodies were stripped from the membranes using Restore Western Stripping Buffer (Pierce). GAPDH, a loading control, contained in each sample was detected with mouse anti-GAPDH monoclonal antibody (MAB374, Chemicon Intl.) and HRP-conjugated goat anti-mouse IgG/IgM (Chemicon Intl.). The protein contents were determined with a BCA protein assay kit (Pierce).

Analysis of the phosphorylation of p38MAPK and NF-κB. HUVECs (50-60% confluent in 6-well plates) were incubated in the presence or absence of 0.1-10 mM glucosamine or 1 mM N-acetylglucosamine for 2 h, and then stimulated with 0.5 ng/ml TNF-α for 10 min at 37˚C. After washing with PBS, the cells were harvested in 250 μl of lysis buffer (1% Triton X-100, 0.5% Nonidet P-40, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM NaVO4, 2 mM p-nitrophenyl phosphate and 1 mM diisopropyl fluorophosphate) containing 1/25 v/v Complete™ (Roche Diagnostic Systems, Mannheim, Germany). After sonication, the lysates were centrifuged at 14,000 x g for 5 min. Samples (10 μg protein/lane) were subjected to 10% SDS-PAGE and blotted, as described in the detection of ICAM-1. Phosphorylated p38MAPK and NF-κB were detected by probing with mouse anti-phosphorylated p38MAPK monoclonal antibody (pT180/ pY182; BD Biosciences Pharmingen, San Diego, CA) and rabbit anti-phosphorylated NF-κB p65 antibody (Ser536; Cell Signaling Technology, Danvers, MA), and HRP-conjugated goat anti-mouse IgG/IgM and HRP-conjugated goat anti-rabbit IgG, respectively.
After stripping, p38MAPK protein, a loading control contained in each sample, was detected by reprobing with mouse anti-p38MAPK (p38/SAPK2α; BD Biosciences Pharmingen) monoclonal antibody and HRP-conjugated goat anti-mouse IgG/IgM.

Detection of O-N-acetylglucosamine-modified proteins by Western blotting. HUVECs in 6-well plates were preincubated in the presence or absence of 0.1-1 mM glucosamine or 1 mM N-acetylglucosamine (GlcNAc). MCP-1, ICAM-1 and GAPDH (loading control) mRNA was detected by real-time RT-PCR. MCP-1 (A) and ICAM-1 (B) mRNA expression was expressed as a ratio relative to TNF-α stimulation alone. Data are the mean ± SEM from 6 independent experiments; *P<0.05.

Figure 1. Effect of glucosamine on TNF-α-induced MCP-1 and ICAM-1 mRNA expression in HUVECs. HUVECs were incubated without (Resting) or with 0.5 ng/ml TNF-α in the absence or presence of 0.1-10 mM glucosamine (GlcN), or 1 and 10 mM N-acetylglucosamine (GlcNAc). MCP-1, ICAM-1 and GAPDH (loading control) mRNA was detected by real-time RT-PCR. MCP-1 (A) and ICAM-1 (B) mRNA expression was expressed as a ratio relative to TNF-α stimulation alone. Data are the mean ± SEM from 6 independent experiments; *P<0.05.

Figure 2. Effect of glucosamine on MCP-1 and ICAM-1 expression in HUVECs. HUVECs were incubated without (Resting) or with 0.5 ng/ml TNF-α in the absence or presence of 0.1-1 mM glucosamine (GlcN) or 1 mM N-acetylglucosamine (GlcNAc). Supernatants and cell lysates were recovered, and MCP-1 (A) and ICAM-1 (B) expression was quantitated by ELISA and Western blotting, respectively. GAPDH (a loading control) was also detected by Western blotting. The ICAM-1 level was expressed as a ratio relative to TNF-α stimulation alone. Data are the mean ± SEM from 6 independent experiments; *P<0.05.

Results

Effect of glucosamine on TNF-α-induced expression of MCP-1 and ICAM-1 mRNA. To evaluate the effect of glucosamine on the MCP-1 and ICAM-1 mRNA expression, we stimulated HUVECs with TNF-α, a cytokine expressed in atherosclerotic lesions, in the absence or presence of glucosamine or N-acetylglucosamine. As shown in Fig. 1, glucosamine dose-dependently inhibited the TNF-α-induced expression of MCP-1 and ICAM-1 mRNA detected by real-time RT-PCR (P<0.05 at 1 and 10 mM glucosamine). In contrast, N-acetylglucosamine, an analogue of glucosamine, did not significantly affect the mRNA expression.

Effect of glucosamine on TNF-α-induced expression of MCP-1 and ICAM-1 proteins. Because glucosamine inhibited MCP-1
and ICAM-1 mRNA expression (Fig. 1), we then examined the effect of glucosamine on the TNF-α-induced expression of MCP-1 and ICAM-1 proteins. Consistent with its suppressive effect on mRNA expression, glucosamine inhibited the protein expression of MCP-1 and ICAM-1 (P<0.05 at 1 mM glucosamine) (Fig. 2). As expected, N-acetylglucosamine did not affect the expression of these proteins. We confirmed that glucosamine further suppressed MCP-1 and ICAM-1 expression at 10 mM (data not shown).

Effect of glucosamine on TNF-α-induced phosphorylation of p38MAPK and NF-κB. TNF-α activates a variety of signaling cascades (such as p38MAPK and NF-κB) which lead to the induction of inflammatory response, including adhesion molecule expression and proinflammatory cytokine production (15). Thus, we examined the involvement of p38MAPK and NF-κB in TNF-α-induced MCP-1 and ICAM-1 expression by using p38MAPK and IKK inhibitors. As shown in Fig. 3, both SB203580, a p38MAPK inhibitor, and BMS-345541, an IKK inhibitor, which down-regulates NF-κB activation, dose-dependently suppressed TNF-α-induced MCP-1 and ICAM-1 expression; 20 μM SB203580 and 4 μM BMS inhibited the expression by 40-50% and 30-80%, respectively, indicating the participation of p38MAPK and NF-κB in the TNF-α-induced MCP-1 and ICAM-1 expression. Furthermore, we evaluated the effects of glucosamine on the TNF-α-induced phosphorylation of p38MAPK and NF-κB. As shown in Fig. 4, glucosamine dose-dependently inhibited the phosphorylation of p38MAPK and NF-κB (P<0.05 at 1 and 10 mM glucosamine), but N-acetylglucosamine did not, as observed for the effects on the MCP-1 and ICAM-1 expression (Figs. 1 and 2). These results suggest that glucosamine suppresses the expression of MCP-1 and ICAM-1 possibly by affecting p38MAPK and NF-κB signaling.

Effect of glucosamine on O-GlcNAc modification. Modification of cellular proteins with O-linked-N-acetylglucosamine is involved in the modulation of cell functions, such as transcription and translation (16,17). Thus, we investigated whether glucosamine induces O-GlcNAc modification, which accounts for the suppressive effect of glucosamine on endothelial cell activation. When the cells were incubated in the presence of 0.1-10 mM glucosamine along with TNF-α, O-GlcNAc modification was observed (P<0.05 at 1 mM glucosamine), whereas TNF-α alone did not induce O-GlcNAc modification (Fig. 5). To note, alloxan (0.5 mM), an inhibitor of O-GlcNAc modification, effectively prevented the glucosamine-induced O-GlcNAc modification (P<0.05) (Fig. 5).
As expected, N-acetylglucosamine did not induce O-GlcNAc modification. We confirmed that 10 mM glucosamine further induced O-GlcNAc modification, which was significantly suppressed by alloxan (data not shown).

Effect of alloxan on the glucosamine-induced suppression of MCP-1 and ICAM-1 protein expression. Glucosamine inhibited MCP-1 and ICAM-1 expression but N-acetylglucosamine did not. Similarly, glucosamine but not N-acetylglucosamine induced O-GlcNAc modification. Since O-GlcNAc modification is involved in the modulation of cell functions (16,17), we investigated the relationship between the glucosamine-induced protein O-GlcNAc modification and suppression of MCP-1 and ICAM-1 expression by using alloxan, which inhibited glucosamine-induced O-GlcNAc modification (Fig. 5). Of importance, alloxan abrogated the glucosamine-induced suppression of MCP-1 and ICAM-1 expression, although the effect was more profound against the suppression of ICAM-1 (Fig. 6). These findings suggest that glucosamine-induced O-GlcNAc modification is involved in the suppression of MCP-1 and ICAM-1 expression.

Discussion
Atherosclerosis is a chronic inflammatory disease which is characterized by infiltration of mononuclear leukocytes and lymphocytes into the intima through the expression of adhesion molecules on endothelial cells. Pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β (IL-1β), are found in atherosclerotic lesions and contribute to the inflammatory process (8,18). Previous studies have shown that these cytokines can induce the expression of cell adhesion molecules and chemokines and lead to the recruitment of leukocytes (19-21).

Here, we evaluated the effect of glucosamine on TNF-α-induced expression of ICAM-1 and MCP-1, which play roles in the process of atherosclerotic plaque formation as an adhesion molecule and a chemoattractant protein, respectively. Upon activation, endothelial cells up-regulate adhesion molecules (such as ICAM-1), and monocytes can bind to endothelium through adhesion molecules. Subsequently, monocytes migrate into the arterial intima, and this process requires a chemoattractant (such as MCP-1).
Gradient. Once monocytes reside in the intima, they become intimal macrophages and internalize modified lipoproteins to become foam cells. Eventually, these macrophages congregate to the central core of atherosclerotic plaques (21).

Glucosamine is used to treat osteoarthritis (9,10) and also exhibits anti-inflammatory actions. In brief, glucosamine suppresses neutrophil functions such as superoxide generation, granule enzyme release and chemotaxis (12), and inhibits platelet aggregation (22). In addition, glucosamine suppresses the activation (such as nitric oxide, PGE2, IL-8 production) of synovioocytes (23). Furthermore, glucosamine inhibits ICAM-1 expression in human retinal pigment epithelial cells (13).

In this study, we investigated the effect of glucosamine on the activation of endothelial cells and revealed that glucosamine but not N-acetylglucosamine inhibits the expression of ICAM-1 and MCP-1 at the mRNA and protein levels (Figs. 1 and 2). In separate experiments, we stimulated endothelial cells with another pro-inflammatory cytokine IL-1β. We confirmed that IL-1β also induced the expression of MCP-1 and ICAM-1, and the expression was similarly suppressed by glucosamine as observed in the TNF-α-induced MCP-1 and ICAM-1 expression (data not shown).

TNF-α activates a variety of signaling cascades (such as p38MAPK and NF-κB pathways) that leads to the induction of inflammatory response (15). We demonstrated using p38MAPK and IKK inhibitors that TNF-α induces the expression of ICAM-1 and MCP-1 via p38MAPK and NF-κB signaling (Fig. 3). Furthermore, we revealed that glucosamine suppressed, not only the expression of MCP-1 and ICAM-1 (Figs. 1 and 2), but also the phosphorylation of p38MAPK and NF-κB (Fig. 4). These observations suggest that glucosamine inhibits endothelial cell activation (i.e., MCP-1 and ICAM-1 expression) possibly via the suppression of intracellular signaling including p38MAPK and NF-κB.

It is now recognized that the addition of O-linked N-acetylglucosamine (O-GlcNac) to target proteins may modulate cellular functions, such as nuclear transport, transcription, translation, cell signaling, apoptosis and cell shape (16,17). In this context, it has been recently found that glucosamine treatment protects rats hearts from ischemia-reperfusion injury, accompanied by the increased O-GlcNac levels and attenuated phosphorylation of p38MAPK (24). To note, Western blotting using anti-O-GlcNac monoclonal antibody revealed that glucosamine but not N-acetylglucosamine induced the O-GlcNac-modification in endothelial cells (Fig. 5), which was negatively correlated with endothelial cell activation (the phosphorylation of p38 MAPK and NF-κB), and the expression of MCP-1 and ICAM-1 (Figs. 1, 2 and 4). Mammalian cells contain O-GlcNac transferase (OGT), an O-GlcNac-modifying enzyme and O-N-acetylglucosaminidase (O-GlcNAcase), an O-GlcNac-modification degrading enzyme (16,17). Thus, we further investigated the effect of alloxan, an OGT inhibitor. Alloxan abrogated not only the glucosamine-induced O-GlcNAc-modification but also the glucosamine-induced suppression of MCP-1 and ICAM-1 expression, and p38MAPK and NF-κB phosphorylation (Figs. 4, 5 and 6). Together these observations suggest that glucosamine modulates endothelial cell activation possibly via O-GlcNAc modification, which likely affects intracellular signaling, such as p38MAPK and NF-κB, and expression of target proteins, such as MCP-1 and ICAM-1.

In conclusion, glucosamine is likely to suppress TNF-α-induced ICAM-1 and MCP-1 expression in endothelial cells, possibly by affecting p38MAPK and NF-κB signal pathways via O-GlcNAc modification. Thus, we speculate that glucosamine affects endothelial cell activation, thereby exhibiting anti-inflammatory action on atherosclerosis. In this context, it is important to note that administration of glucosamine significantly reduced atherosclerotic lesions in the aortic roots of apoE-deficient mice (25). The in vivo effect of glucosamine on atherosclerotic disorders should be carefully evaluated in the future.

Acknowledgements

We thank Drs Yuko Tsutsumi-Ishii and Shin Yomogida for the helpful discussion during the research. This work was supported in part by a grant from the Atopy (Allergy) Research Center, Juntendo University and a Grant-in-Aid for 21st Century COE Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References


